Barbara S. Fox, Ph.D., CEO. Dr. Fox is an experienced entrepreneur and scientist. Dr. Fox was the past founder, President and Chief Scientific Officer of Recovery Pharmaceuticals, a company developing and marketing medications for the treatment of addiction. Prior to founding Recovery Pharmaceuticals in 1998, she was Vice President, Immunology at ImmuLogic Pharmaceutical Corp. She joined ImmuLogic in 1993, having served on the faculty of the University Maryland School of Medicine, Baltimore, as Associate Professor of Medicine with tenure in the Division of Rheumatology and Clinical Immunology, Dept. of Medicine. Dr. Fox received her BA in Chemistry from Bryn Mawr College and her Ph.D. in Chemistry from MIT. Dr. Fox trained as a post-doc in cellular immunology at the NIH.

Anne B. Baia, CPA, MST, MBA, CFO. Ms. Baia has over 20 years experience in accounting, finance, business development and strategic management. She has been involved in raising over $25M in venture equity and has led efforts to secure several debt facilities. Most recently Ms. Baia has served as a consultant providing interim CFO and COO services to a variety of venture-backed life science firms. Ms. Baia has held senior finance, operations, and business development positions at Descartes Therapeutics (VP, Finance & Administration), Mercury Therapeutics (CFO & V.P. Business Development), and Phylos (V.P., Finance & Administration and Managing Director, Phylos GmbH). Prior to Phylos, Ms. Baia worked in public accounting specializing in early stage technology-based companies. She holds a Bachelor of Science in Management (cum laude) and a MBA and a MST (high distinction) from Bentley Graduate School of Business. Ms. Baia is a Certified Public Accountant, a member of the American Institute of Certified Public Accountants, a member of BIO’s Business Advisory Board, and Chair of the Massachusetts Biotechnology Finance Committee.

Eileen F. Bostwick, Ph.D., VP Product Development. Dr. Bostwick is an expert in the development of oral pharmaceutical products similar to those being developed by Avaxia. She previously served as Vice President, Research and Development at GalaGen Inc., a company that was spun out of Land O’Lakes to develop pharmaceutical products from bovine milk and colostrum. At Galagen, she led the R&D, regulatory and clinical efforts to advance colostrum-based biologic products to human clinical testing. She managed all aspects of the development process for similar products, including the technical aspects of bovine immunizations and colostrum collection, incoming quality control and evaluation of raw materials, coordination of bulk pharmaceutical manufacturing and analysis, establishment of product/process specifications, validation of analytical methods, development of preclinical testing protocols and interactions with the USDA, CFSAN and FDA on both CMC and clinical issues. Since leaving GalaGen, she has been a consultant and Vice President, Research and Development at BioBalance Corp. Dr. Bostwick holds a Ph.D. in Animal Physiology from the University of Minnesota.

David Poorvin, Ph.D., Director. Dr. Poorvin is an Executive-in-Residence at Oxford Bioscience Partners, is President of his own consulting firm and sits on the board of directors of several public and private biotech companies. He most recently retired from Schering-Plough Corporation as Vice President of their Business Development operations where he negotiated licenses, joint ventures and acquisitions of pharmaceutical products and research technologies. At the time of his retirement, 70% of Schering-Plough’s pharmaceutical sales were derived from third party products acquired during his tenure. Prior to spending 14 years in Business Development, Dr. Poorvin held positions of Director of Clinical Research at Schering-Plough and Pfizer Pharmaceuticals. He was responsible for several NDA programs and product approvals at both companies, including such drugs as Procardia and Imdur. Poorvin started his career in the pharmaceutical industry at Lederle Laboratories, where he directed pre-clinical research in the cardiovascular area.